Actively Recruiting
Therapeutic Relevance of Abnormal Airway Morphology in Asthma
Led by McMaster University · Updated on 2025-09-11
242
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT), required to investigate this. This study will use these imaging methods to visually assess and measure individual patients' airways and determine whether abnormal airway structures impact how well they respond to inhaled and orally delivered medications. We anticipate finding that abnormal airway structures make inhaled medications less effective, but that they do not affect the response to oral medications.
CONDITIONS
Official Title
Therapeutic Relevance of Abnormal Airway Morphology in Asthma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent.
- Able and willing to comply with the study protocol.
- Male or female aged 18 years or older.
- Asthma diagnosed by a respiratory physician.
- Airway hyperresponsiveness (methacholine PC20 ≤8mg/mL) and/or bronchodilator reversibility (post-bronchodilator FEV1 improvement ≥200mL and 12%) in the past 6 months.
- ACQ score of 1.5 or higher during screening.
- Sputum eosinophils ≥3% and/or FeNO ≥35ppb during screening.
You will not qualify if you...
- Current smoker or smoked at least 1 cigarette, vape, pipe, cigar, or marijuana at least 1 day per month within 12 months before screening.
- Pregnant or breastfeeding.
- Non-English speaking.
- Used oral corticosteroids within 1 month before screening.
- Received biologic therapy within 6 months before screening.
- Unable to perform proper metered dose inhaler technique during screening.
- Other pulmonary diseases requiring treatment within 12 months before screening (e.g., COPD, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis).
- Unable to undergo MRI due to implanted devices, metal in the body, or severe claustrophobia or other physical or psychological conditions preventing MRI.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N4A6
Actively Recruiting
2
Western University
London, Ontario, Canada, N6A 3K7
Not Yet Recruiting
Research Team
S
Sarah Svenningsen, PhD
CONTACT
Y
Yonni Friedlander, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here